Tarsus Pharmaceuticals, Inc. TARS
Set alert
74.85 USD +0.65 +0.88%
At close · Oct 30
75.55 +0.70 +0.94%
After hours · Oct 30, 4:34 PM ET
74.30 Day range 76.27
56.11 52-week range 90.78
- YTD
- -8.59%
- 1 year
- +8.54%
- Open
- 74.99
- Prev close
- 74.20
- Mkt cap
- 3.50B
- Vol
- 595.21K
- Avg vol
- 835.42K
- EPS
- -1.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 74.30
- High
- 76.27
- Forward P/E
- -150.06
- Beta
- 0.45
- Short ratio
- 6.62
- Inst. own
- 99.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 75.09
- 200-d avg
- 67.78
- 1y target
- 99.56
MAX chart
Events in this range
- Aug 6, 2025Earnings: -0.48; estimate -0.33; surprise -45.45%
- Nov 4, 2025Earnings: -0.3; estimate -0.35; surprise 14.29%
- Feb 23, 2026Earnings: -0.2; estimate -0.103; surprise -94.17%
- May 4, 2026Rating: HC Wainwright & Co. · Buy → Buy
- May 6, 2026Earnings: -0.16; estimate -0.40167; surprise 60.17%
- Jul 9, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jul 21, 2026Rating: Guggenheim · Buy → Buy
- Jul 31, 2026Rating: Mizuho · Outperform → Outperform
- Aug 6, 2026Earnings: -0.43; estimate -0.19177; surprise -124.23%
- Aug 12, 2026Rating: Oppenheimer · Outperform → Outperform
- Sep 8, 2026Rating: Jefferies · Buy → Buy
- Nov 3, 2026Earnings: —; estimate -1.46; surprise —%
Signals (117)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| RSI: Overbought | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 9 months ago |
| RSI: Overbought | Nov 17, 2025 | 11 months ago |
| RSI: Overbought | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 10, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 20, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| RSI: Overbought | Nov 25, 2024 | 1 year ago |
| RSI: Overbought | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 9, 2024 | 2 years ago |
| SMA: Bullish | Aug 26, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | May 20, 2024 | 2 years ago |
| MACD: Sell Signal | May 20, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 29, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| RSI: Overbought | Mar 25, 2024 | 2 years ago |
| RSI: Overbought | Jan 22, 2024 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| SMA: Bearish | Nov 27, 2023 | 2 years ago |
| SMA: Bearish | Nov 27, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 13, 2023 | 2 years ago |
| SMA: Bullish | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Oct 9, 2023 | 3 years ago |
| SMA: Bearish | Oct 9, 2023 | 3 years ago |
| SMA: Bullish | Sep 25, 2023 | 3 years ago |
| SMA: Bullish | Sep 18, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| RSI: Overbought | Jul 17, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bullish | Feb 13, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| MACD: Sell Signal | Dec 12, 2022 | 3 years ago |
| SMA: Bearish | Dec 5, 2022 | 3 years ago |
| SMA: Bearish | Dec 5, 2022 | 3 years ago |
| SMA: Bullish | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| SMA: Bearish | Oct 17, 2022 | 4 years ago |
| SMA: Bullish | Sep 19, 2022 | 4 years ago |
| SMA: Bullish | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | May 2, 2022 | 4 years ago |
| MACD: Sell Signal | May 2, 2022 | 4 years ago |
| RSI: Oversold | May 2, 2022 | 4 years ago |
| SMA: Bullish | Apr 4, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 4, 2022 | 4 years ago |
| SMA: Bearish | Mar 14, 2022 | 4 years ago |
| SMA: Bullish | Feb 28, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 3, 2022 | 4 years ago |
| SMA: Bearish | Nov 15, 2021 | 4 years ago |
| SMA: Bearish | Nov 8, 2021 | 4 years ago |
| SMA: Bullish | Nov 1, 2021 | 5 years ago |
| SMA: Bearish | Oct 18, 2021 | 5 years ago |
| SMA: Bullish | Oct 11, 2021 | 5 years ago |
| MACD: Buy Signal | Oct 11, 2021 | 5 years ago |
| SMA: Bullish | Oct 4, 2021 | 5 years ago |
| SMA: Bearish | Sep 6, 2021 | 5 years ago |
| SMA: Bullish | Aug 30, 2021 | 5 years ago |
| SMA: Bearish | Jun 21, 2021 | 5 years ago |
| SMA: Bearish | Jun 21, 2021 | 5 years ago |
| SMA: Bullish | Jun 7, 2021 | 5 years ago |
| SMA: Bullish | May 17, 2021 | 5 years ago |
| SMA: Bearish | Feb 8, 2021 | 5 years ago |
| SMA: Bullish | Feb 1, 2021 | 5 years ago |
| SMA: Bearish | Jan 25, 2021 | 5 years ago |
Key statistics
- Market cap
- 3.51B
- Enterprise value
- 2.90B
- Trailing P/E
- 0.00
- Forward P/E
- -150.06
- PEG ratio
- 0.00
- Price / sales
- 5.79
- Price / book
- 9.36
- EPS (TTM)
- -1.08
- Beta
- 0.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -7.66%
- Revenue (TTM)
- 606.33M
- Revenue growth
- 69.40%
- Free cash flow
- 67.47M
- Total cash
- 449.69M
- Total debt
- 88.81M
- Return on equity
- -13.68%
- Shares outstanding
- 46.79M
- Short % of float
- 12.63%
- 50-day average
- 75.09
- 200-day average
- 67.78
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 99.56 +33.0% upside
Now 74.85
- Target (low)
- 84.00
- Target (mean)
- 99.56
- Target (high)
- 116.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -1.77.
Financials — quick view
TARS Revenue — quarterly 173.91M
TARS Net income — quarterly -18.55M
TARS EPS — quarterly -0.43
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -1.46 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.19177 | -0.43 | -0.24 | -124.23% |
| May 6, 2026 | Mar 31, 2026 | -0.40167 | -0.16 | +0.24 | +60.17% |
| Feb 23, 2026 | Dec 31, 2025 | -0.103 | -0.20 | -0.10 | -94.17% |
| Nov 4, 2025 | Sep 30, 2025 | -0.35 | -0.30 | +0.05 | +14.29% |
| Aug 6, 2025 | Jun 30, 2025 | -0.33 | -0.48 | -0.15 | -45.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 2026 | Jefferies | main | Buy | Buy |
| Aug 12, 2026 | Oppenheimer | main | Outperform | Outperform |
| Jul 31, 2026 | Mizuho | main | Outperform | Outperform |
| Jul 21, 2026 | Guggenheim | main | Buy | Buy |
| Jul 9, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tarsusrx.com
News
- Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
- Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
- Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
- Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options
- Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
- Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target
- Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis
- Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target
- Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105
- Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Your note
Sign in to keep a note on TARS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AZAMIAN BOBAK R | Chief Executive Officer | Sale | Sep 3, 2026 | 0 |
| FARROW JEFFREY S | Chief Financial Officer | Sale | Jun 15, 2026 | 56,801 |
| GOLDBERG ANDREW D | Director | Conversion of Exercise of derivative security | Jun 11, 2026 | 19,654 |
| LIN ELIZABETH YEU | Officer | Sale | Sep 3, 2026 | 0 |
| LINK WILLIAM J | Director | Sale | Sep 14, 2026 | 94,487 |
| MOTTIWALA AZIZ | Officer | Sale | Mar 18, 2026 | 61,480 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.82% | 3,856,137 | 289.33M | Jun 29, 2026 |
| Deep Track Capital, Lp | 7.44% | 3,666,768 | 275.12M | Jun 29, 2026 |
| RTW Investments LP | 6.81% | 3,357,059 | 251.88M | Jun 29, 2026 |
| Jupiter Topco LLC | 5.70% | 2,808,796 | 210.74M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 5.63% | 2,775,649 | 208.26M | Jun 29, 2026 |
| Morgan Stanley | 3.71% | 1,827,082 | 137.09M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.63% | 1,295,411 | 97.19M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.20% | 1,084,124 | 81.34M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.93% | 457,872 | 34.35M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.92% | 455,507 | 34.18M | Jun 29, 2026 |
| Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. | 0.83% | 408,226 | 30.63M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.79% | 391,513 | 29.38M | Sep 29, 2026 |